Pancreatic Cancer Research

ResearcherBaylor College of MedicineActive in the last 2 years

Jingxuan Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3265-161X; OpenAlex author ID A5011227285. Sources: OpenAlex.

Their work

Papers
32 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
121
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 4 papers · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 32

  1. Spatial evolution of a cachexia-promoting microenvironment in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.09.012↗
  2. Glycosylated Chitosan Inhibits Pancreatic Cancer Metastasis by Blocking the Caveolin Signaling Pathway. Co-author DOI 10.3390/cancers18091473↗
  3. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Co-author DOI 10.1016/j.ccell.2024.03.009↗
  4. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  5. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer. First author DOI 10.1053/j.gastro.2022.02.017↗
  6. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.06.058↗
  7. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103271↗
  8. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.12.077↗
  9. Interplay of Tumor Microenvironment Factors and Cancer Stem Cell Enrichment in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2021.09.024↗
  10. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  11. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancrea… Co-author DOI 10.1053/j.gastro.2019.10.038↗
  12. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  13. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis. Co-author DOI 10.1158/1078-0432.ccr-18-4113↗
  14. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. First author DOI 10.1158/1078-0432.ccr-18-0263↗
  15. Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. First author DOI 10.1158/1078-0432.ccr-18-1126↗
  16. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/m… Co-author DOI 10.1038/srep19222↗
  17. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  18. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.04.009↗
  19. ZIP4 silencing improves bone loss in pancreatic cancer. Co-author DOI 10.18632/oncotarget.4667↗
  20. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Co-author DOI 10.1186/1476-4598-13-187↗
  21. CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. First author DOI 10.18632/oncotarget.1890↗
  22. ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. Co-author DOI 10.2174/1566524013666131217112921↗
  23. ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer. Co-author DOI 10.4161/cc.28111↗
  24. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. First author DOI 10.1002/emmm.201302507↗
  25. Study human pancreatic cancer in mice: how close are they? Co-author DOI 10.1016/j.bbcan.2012.11.001↗
  26. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Co-author DOI 10.2174/1566524011313040001↗
  27. Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer. Co-author DOI 10.2174/1566524011313030009↗
  28. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2012.05.007↗
  29. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. First author DOI 10.1016/j.canlet.2012.05.013↗
  30. Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. Co-author DOI 10.1111/j.1582-4934.2011.01478.x↗
  31. Genomic sequencing of key genes in mouse pancreatic cancer cells. Co-author DOI 10.2174/156652412799218868↗
  32. Overcoming drug resistance in pancreatic cancer. Co-author DOI 10.1517/14728222.2011.566216↗

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Li · 17 shared papers, 2011–2026 · strength 1.53
  2. Courtney W. Houchen · 10 shared papers, 2015–2026 · strength 1.27
  3. Mingyang Liu · 10 shared papers, 2018–2024 · strength 1.10
  4. Zhijun Zhou · 9 shared papers, 2018–2024 · strength 1.05
  5. Xiuhui Shi · 7 shared papers, 2021–2024 · strength 0.90
  6. Xianjun Yu · 9 shared papers, 2011–2021 · strength 0.43
  7. Wei R. Chen · 1 shared paper, 2026 · strength 0.33
  8. Yong Li · 1 shared paper, 2026 · strength 0.33
  9. Hanxiang Zhan · 3 shared papers, 2020–2021 · strength 0.30
  10. Xiaobo Cui · 6 shared papers, 2013–2020 · strength 0.28
  11. Yi Qin · 4 shared papers, 2013–2021 · strength 0.25
  12. Yu‐Qing Zhang · 4 shared papers, 2013–2020 · strength 0.25
  13. Lei Zheng · 2 shared papers, 2018–2024 · strength 0.23
  14. Yumeng Hu · 1 shared paper, 2026 · strength 0.23
  15. Shunrong Ji · 3 shared papers, 2014–2021 · strength 0.22
  16. Min Li · 4 shared papers, 2012–2019 · strength 0.22
  17. Martín E. Fernández-Zapico · 4 shared papers, 2013–2020 · strength 0.21
  18. Jin Xu · 4 shared papers, 2014–2019 · strength 0.21
  19. Jiang Long · 5 shared papers, 2011–2016 · strength 0.19
  20. Putao Cen · 5 shared papers, 2012–2015 · strength 0.18
  21. Alex Arreola · 1 shared paper, 2024 · strength 0.17
  22. Ryan David Nipp · 1 shared paper, 2024 · strength 0.17
  23. Yuqing Zhang · 1 shared paper, 2021 · strength 0.17
  24. Min Li · 1 shared paper, 2021 · strength 0.17
  25. Quanxing Ni · 3 shared papers, 2014–2019 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.